Search - tctmd.com

Displaying 41 - 60 of 653

Sort: Relevancy | Date

News Daily News

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

Todd Neale

March 15, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2024

Shelley Wood

February 01, 2024

News Daily News

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Yael L. Maxwell

January 10, 2024

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

News Daily News

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

Yael L. Maxwell

November 08, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2023

Shelley Wood

November 01, 2023

Presentation TCT 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

Presenter: Hyunki LEE

October 25, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Presentation TCT 2023

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

Presenter: Seong Huan Choi

October 25, 2023

Presentation TCT 2023

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Presenter: Ji-Yeon Kim

October 25, 2023

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2023

TCT 557: Real World Adherence to High Potency P2Y12 Inhibitor Therapy in Patients Treated for ST Elevation Myocardial Infarction

Presenter: Wadie David

October 24, 2023

Presentation TCT 2023

TCT 44: P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Presenter: Seung-Yul Lee

October 24, 2023

News Daily News

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Yael L. Maxwell

October 09, 2023

News Daily News

Pre-TAVI PCI Linked to More Late Bleeding, With Implications for Survival

L.A. McKeown

September 14, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

Podcast TCTMD Talking Points

The PANTHER Trial

September 06, 2023

News Daily News

Unguided De-escalation, Short DAPT the Best Strategies in ACS: Meta-analysis

Yael L. Maxwell

September 05, 2023

News Conference News ESC 2023

STOPDAPT-3: Don’t Skip Out on Aspirin Immediately After PCI

Todd Neale

August 26, 2023

News Conference News ESC 2023

Avoid Using Prasugrel With Cangrelor During PCI, SWAP-6 Affirms

Todd Neale

August 22, 2023

Advertisement

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

TCTMD’s Top 10 Most Popular Stories for January 2024

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Guiding DAPT Based on Genes or Platelet Tests Still ‘Tempting’

TCTMD’s Top 10 Most Popular Stories for October 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

TCT 557: Real World Adherence to High Potency P2Y12 Inhibitor Therapy in Patients Treated for ST Elevation Myocardial Infarction

TCT 44: P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Pre-TAVI PCI Linked to More Late Bleeding, With Implications for Survival

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

The PANTHER Trial

Unguided De-escalation, Short DAPT the Best Strategies in ACS: Meta-analysis

STOPDAPT-3: Don’t Skip Out on Aspirin Immediately After PCI

Avoid Using Prasugrel With Cangrelor During PCI, SWAP-6 Affirms

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content